Skip to main content
Cowhey Center on Global Transformation CCGT

Andrew ("Drew") Senyei, M.D.

Andrew ("Drew") Senyei, M.D.
Andrew ("Drew") Senyei, M.D., is a physician, venture capitalist, and inventor with more than 30 years of experience in the building of emerging technology and healthcare companies. Dr. Senyei served as Managing Director of Enterprise Partners Venture Capital for more than 25 years with $1.1B under management. He was the founding investor of multiple healthcare technology companies including Nuvasive (NASDAQ: NUVA), one of the largest minimally non-invasive orthopedic companies in the U.S. Dr. Senyei has served on the boards of more than 30 private and public companies. He remains actively involved with early stage angel investing in a variety of high-tech industries. He is a senior advisor to Healthpoint Capital, the leading private equity firm in musculoskeltal healthcare. He currently serves on The Board of Trustees at Northwestern University where he is the past chair of the Medicine Committee. Dr. Senyei is also a member of UC San Diego Foundation board and a founding member of the UC San Diego School of Global Policy and Strategy's 21st Century China Center leadership advisory board. He is co-chair of the advisory board of the California Institute for Telecommunications and Information Technology (Calit2) and is a former Chair of the UC San Diego Jacobs School of Engineering Advisory Council. Dr. Senyei was named one of the Top 100 Venture Capitalists in the U.S. on Forbes magazine's Midas Touch List and was also the recipient of the Ernst & Young San Diego Master Entrepreneur Award. He is credited with 30 patents and more than 45 publications in peer-reviewed journals, including the New England Journal of Medicine and Proceedings of the National Academy of Science. Early in his career he was the inventor of the first FDA-approved test to predict and help manage pre-term birth, which has been used by more than 8 million women worldwide. Dr. Senyei received his M.D. from Northwestern University and completed his residency training at the University of California, Irvine, where he served on the faculty prior to becoming active full-time with venture capital funding of early stage technology companies.